Skip to main content
NCBI home page
Indian Journal of Psychiatry logoLink to Indian Journal of Psychiatry
. 1998 Jul-Sep;40(3):201–211.

NEUROBIOLOGICAL CHARACTERIZATION OF BIPOLAR AFFECTIVE DISORDERS : A FOCUS ON TARDIVE DYSKINESIA AND SOFT NEUROLOGICAL SIGNS IN RELATION TO SERUM DOPAMINE BETA HYDROXYLASE ACTIVITY

Utpal Goswami *,*, S Basu †, U Khastgir ‡, Unnati Kumar §, R Chandrasekaran , BN Gangadhar #, Rajesh Sagar ♠, JS Bapna ♥, SM Channabasavanna ⯁, P Brain Moore *, I Nicol Ferrier **
PMCID: PMC2966593  PMID: 21494474

Abstract

In this study, the prognostic determinants were investigated involving bipolar patients classified into two groups-one with favourable course and outcome, and the other with clearly unfavourable prognosis, based on certain recommended criteria, with intermediate prognosis were excluded. As compared to the poor prognosis group, the good prognosis group had lower social dysfunctions, lower ratings on psychopathotogy fewer indicators of neurodysfunction in form of neurological soft signs (NSS) and tardive dyskinesia (TD). The poor prognosis group was characterized by: (i) older age at onset; (ii) more manic than depressive episodes (5:1) and (HI) lower levels of serum dopamine-β-hydroxylase activity (DBH). The association between poor prognosis bipolar disorder having neuroleptic intolerance (TD and NSS) with low serum DBH, suggests that it is genetically governed. Further research in this direction seems in order, particularly the follow up of first episode manic disorders.

Keywords: Bipolar disorder, dopamine-β-hydroxylase, prognosis, neurological “soft” signs, tardive dyskinesia, neurodysfunction

Full Text

The Full Text of this article is available as a PDF (475.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altshuler L. L. Bipolar disorder: are repeated episodes associated with neuroanatomic and cognitive changes? 1993 Apr 15-May 1Biol Psychiatry. 33(8-9):563–565. doi: 10.1016/0006-3223(93)90093-s. [DOI] [PubMed] [Google Scholar]
  2. Altshuler L. L., Conrad A., Hauser P., Li X. M., Guze B. H., Denikoff K., Tourtellotte W., Post R. Reduction of temporal lobe volume in bipolar disorder: a preliminary report of magnetic resonance imaging. Arch Gen Psychiatry. 1991 May;48(5):482–483. doi: 10.1001/archpsyc.1991.01810290094018. [DOI] [PubMed] [Google Scholar]
  3. Bech P., Rafaelsen O. J., Kramp P., Bolwig T. G. The mania rating scale: scale construction and inter-observer agreement. Neuropharmacology. 1978 Jun;17(6):430–431. doi: 10.1016/0028-3908(78)90022-9. [DOI] [PubMed] [Google Scholar]
  4. Beckmann H., Jakob H. Prenatal disturbances of nerve cell migration in the entorhinal region: a common vulnerability factor in functional psychoses? J Neural Transm Gen Sect. 1991;84(1-2):155–164. doi: 10.1007/BF01249120. [DOI] [PubMed] [Google Scholar]
  5. Carlson G. A., Kotin J., Davenport Y. B., Adland M. Follow-up of 53 bipolar manic-depressive patients. Br J Psychiatry. 1974 Feb;124(579):134–139. doi: 10.1192/bjp.124.2.134. [DOI] [PubMed] [Google Scholar]
  6. Coffman J. A., Bornstein R. A., Olson S. C., Schwarzkopf S. B., Nasrallah H. A. Cognitive impairment and cerebral structure by MRI in bipolar disorder. Biol Psychiatry. 1990 Jun 1;27(11):1188–1196. doi: 10.1016/0006-3223(90)90416-y. [DOI] [PubMed] [Google Scholar]
  7. Cohen G., Spina M. B. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol. 1989 Nov;26(5):689–690. doi: 10.1002/ana.410260518. [DOI] [PubMed] [Google Scholar]
  8. Dolan R. J., Calloway S. P., Mann A. H. Cerebral ventricular size in depressed subjects. Psychol Med. 1985 Nov;15(4):873–878. doi: 10.1017/s0033291700005110. [DOI] [PubMed] [Google Scholar]
  9. Frank E., Prien R. F., Jarrett R. B., Keller M. B., Kupfer D. J., Lavori P. W., Rush A. J., Weissman M. M. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991 Sep;48(9):851–855. doi: 10.1001/archpsyc.1991.01810330075011. [DOI] [PubMed] [Google Scholar]
  10. Glazer W. M., Morgenstern H., Jeste D. V., Zahner G., Hafez H. M., Benarroche C. L. Serum dopamine beta hydroxylase activity and tardive dyskinesia. Psychoneuroendocrinology. 1987;12(4):289–294. doi: 10.1016/0306-4530(87)90053-9. [DOI] [PubMed] [Google Scholar]
  11. Graham D. G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol. 1978 Jul;14(4):633–643. [PubMed] [Google Scholar]
  12. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56–62. doi: 10.1136/jnnp.23.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jeste D. V., Potkin S. G., Sinha S., Feder S., Wyatt R. J. Tardive dyskinesia--reversible and persistent. Arch Gen Psychiatry. 1979 May;36(5):585–590. doi: 10.1001/archpsyc.1979.01780050095012. [DOI] [PubMed] [Google Scholar]
  14. Johnstone E. C., Owens D. G., Crow T. J., Frith C. D., Alexandropolis K., Bydder G., Colter N. Temporal lobe structure as determined by nuclear magnetic resonance in schizophrenia and bipolar affective disorder. J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):736–741. doi: 10.1136/jnnp.52.6.736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kolakowska T., Williams A. O., Jambor K., Ardern M. Schizophrenia with good and poor outcome. III: Neurological 'soft' signs, cognitive impairment and their clinical significance. Br J Psychiatry. 1985 Apr;146:348–357. doi: 10.1192/bjp.146.4.348. [DOI] [PubMed] [Google Scholar]
  16. Liddle P. F., Barnes T. R., Speller J., Kibel D. Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia. Br J Psychiatry. 1993 Dec;163:776–780. doi: 10.1192/bjp.163.6.776. [DOI] [PubMed] [Google Scholar]
  17. Markianos M., Tripodianakis J., Garelis E. Neurochemical studies on tardive dyskinesia. II. Urinary methoxyhydroxyphenylglycol and plasma dopamine-beta-hydroxylase. Biol Psychiatry. 1983 Mar;18(3):347–354. [PubMed] [Google Scholar]
  18. Matuzas W., Meltzer H. Y., Uhlenhuth E. H., Glass R. M., Tong C. Plasma dopamine-beta-hydroxylase in depressed patients. Biol Psychiatry. 1982 Dec;17(12):1415–1424. [PubMed] [Google Scholar]
  19. Meltzer H. Y., Cho H. W., Carroll B. J., Russo P. Serum dopamine-beta-hydroxylase activity in the affective psychoses and schizophrenia. Decreased activity in unipolar psychotically depressed patients. Arch Gen Psychiatry. 1976 May;33(5):585–591. doi: 10.1001/archpsyc.1976.01770050047007. [DOI] [PubMed] [Google Scholar]
  20. Meltzer H. Y. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull. 1992;18(3):515–542. doi: 10.1093/schbul/18.3.515. [DOI] [PubMed] [Google Scholar]
  21. Mukherjee S., Rosen A. M., Caracci G., Shukla S. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry. 1986 Apr;43(4):342–346. doi: 10.1001/archpsyc.1986.01800040052008. [DOI] [PubMed] [Google Scholar]
  22. Nagatsu T., Udenfriend S. Photometric assay of dopamine- -hydroxylase activity in human blood. Clin Chem. 1972 Sep;18(9):980–983. [PubMed] [Google Scholar]
  23. Nasrallah H. A., Tippin J., McCalley-Whitters M. Neurological soft signs in manic patients. A comparison with Schizophrenic and control groups. J Affect Disord. 1983 Feb;5(1):45–50. doi: 10.1016/0165-0327(83)90035-6. [DOI] [PubMed] [Google Scholar]
  24. Okada T., Ohta T., Shinoda T., Kato T., Ikuta K. Dopamine-beta-hydroxylase activity in serum and cerebrospinal fluid in neuropsychiatric diseases. Neuropsychobiology. 1976;2(2-3):139–144. doi: 10.1159/000117542. [DOI] [PubMed] [Google Scholar]
  25. Puzyński S., Rode A., Załuska M. Aktywnoś beta-hydroksylazy dopaminy w osoczu chorych z endogennymi zespołami dekpresyjnymi. Psychiatr Pol. 1980 Nov-Dec;14(6):581–586. [PubMed] [Google Scholar]
  26. Schanberg S. M., Stone R. A., Kirshner N., Gunnells J. C., Robinson R. R. Plasma dopamine beta-hydroxylase: a possible aid in the study and evaluation of hypertension. Science. 1974 Feb 8;183(4124):523–525. doi: 10.1126/science.183.4124.523. [DOI] [PubMed] [Google Scholar]
  27. Schooler N. R., Kane J. M. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982 Apr;39(4):486–487. doi: 10.1001/archpsyc.1982.04290040080014. [DOI] [PubMed] [Google Scholar]
  28. Shopsin B., Freedman L. S., Goldstein M., Gershon S. Serum dopamine- -hydroxylase (D H) activity and affective states. Psychopharmacologia. 1972;27(1):11–16. doi: 10.1007/BF00421952. [DOI] [PubMed] [Google Scholar]
  29. Simpson G. M., Lee J. H., Zoubok B., Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 1979 Aug 8;64(2):171–179. doi: 10.1007/BF00496058. [DOI] [PubMed] [Google Scholar]
  30. Spitzer R. L., Endicott J., Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978 Jun;35(6):773–782. doi: 10.1001/archpsyc.1978.01770300115013. [DOI] [PubMed] [Google Scholar]
  31. Yassa R., Schwartz G. Depression as a predictor in the development of tardive dyskinesia. Biol Psychiatry. 1984 Mar;19(3):441–444. [PubMed] [Google Scholar]

Articles from Indian Journal of Psychiatry are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES